<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> &lt;2.80 mmol/l was associated with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the 1) interaction between low <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:mp ids='MP_0002871'>albuminuria</z:mp> and 2) interaction between copresence of these two risk factors and <z:chebi fb="0" ids="35664">statin</z:chebi> use for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We analyzed prospective data for 3,793 Chinese type 2 diabetic patients who remained naive for <z:chebi fb="0" ids="35664">statin</z:chebi> treatment and 1,483 patients in whom <z:chebi fb="0" ids="35664">statin</z:chebi> treatment was initiated during a median follow-up period of 5.24 years </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Biological interactions were estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) </plain></SENT>
<SENT sid="5" pm="."><plain>RERI &gt; 0, AP &gt; 0, or S &gt; 1 indicates biological interaction </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In 3,793 statin-naive type 2 diabetic patients, copresence of low <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:mp ids='MP_0002871'>albuminuria</z:mp> increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk by 2.8-fold (hazard ratio 2.77 [95% CI 1.78-4.31]) with significant biological interactions (RERI 1.05 [0.04-2.06]; AP 0.38 [0.09-0.66]) </plain></SENT>
<SENT sid="7" pm="."><plain>In the whole cohort of 5,276 type 2 diabetic patients, there was interaction between nonuse of <z:chebi fb="0" ids="35664">statins</z:chebi> and copresence of low <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:mp ids='MP_0002871'>albuminuria</z:mp> with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk (RERI 2.87 [0.64-5.09] and AP 0.60 [0.29-0.90]) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> nonusers with <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> &lt;2.80 mmol/l and albumunuria had a 4.9-fold risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> compared with <z:chebi fb="0" ids="35664">statin</z:chebi> users with or without both risk factors </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, there was interaction between low <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:mp ids='MP_0002871'>albuminuria</z:mp> with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks </plain></SENT>
<SENT sid="10" pm="."><plain>The latter was attenuated in the presence of <z:chebi fb="0" ids="35664">statin</z:chebi> treatment </plain></SENT>
</text></document>